Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Genomic Urine Testing Market?

The market size for genomic urine testing has seen a significant expansion in the last few years. Forecasts predict it will climb from $0.90 billion in 2024 to $1.01 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 12.9%. The surge in the historic timeframe is ascribed to the escalating occurrences of urologic cancers, the mounting requirement for early cancer detection, increased consciousness about precision medicine, a rising incidence of genetic disorders, and increased funding in biomarker discovery.

What Growth Rate Is Forecasted for the Genomic Urine Testing Market by 2029?

In the coming years, the genomic urine testing market is expected to experience significant growth, reaching a total worth of $1.62 billion by 2029, with an annual compound growth rate of 12.5%. The forecasted growth could be attributed to various factors including elevated adoption of liquid biopsy techniques, an increased focus on personalized medication, a surge in chronic kidney disease rates, a greater emphasis on home-based diagnostic testing alternatives, and an escalated use of multi-omics methods in urine testing. Some of the emerging trends during this period comprise the development of non-invasive diagnostic pathways, creation of test panels with high sensitivity, incorporation of machine learning frameworks, advancements in urine exosome isolation, and innovations in single-cell urine sequencing.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23408&type=smp

Which Key Companies Are Shaping the Future of the Genomic Urine Testing Market?

Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ​Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd

Which Factors Are Driving Demand in the Genomic Urine Testing Industry?

The growth of the genomic urine testing market is anticipated to be driven by the mounting burden of chronic kidney disease. Characterized as a condition where the kidneys become impaired, unable to effectively filter blood, leading to a toxic accumulation of waste and fluids in the body, chronic kidney disease is becoming increasingly prevalent due to the rising incidence of diabetes. This increase stems from the fact that elevated blood sugar levels can damage the blood vessels in the kidneys, thereby hampering their filtering capacity. Genomic urine testing proves invaluable in managing chronic kidney disease, offering early detection of genetic markers, thus enabling necessary interventions and a higher degree of personalization in treatment plans. Such testing results in more precise monitoring, mitigating disease advancement and improving patient outcomes. For example, the Australian Institute of Health and Welfare, an Australian government agency, highlighted a rise in chronic kidney disease mortality rates by 4.2% in 2021, reaching 6.2% in 2022. Thus, making the rise in chronic kidney disease a key driver for the expansion of the genomic urine testing market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23408&type=smp

How Is the Genomic Urine Testing Market Segmented by Several Divisions?

The genomic urine testing market covered in this report is segmented –

1) By Testing Type: Deoxyribonucleic Acid (DNA) Testing, Ribonucleic Acid (RNA) Testing, Microbial Testing, Epigenetic Testing

2) By Distribution Channel: Hospital Pharmacies, Mail Order Pharmacies, Speciality Pharmacies

3) By Application: Cancer Diagnosis, Infectious Diseases, Genetic Disorder Screening, Health Monitoring

4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutions, Other End Users

Subsegments

1) By Deoxyribonucleic Acid Testing: Germline Mutation Analysis, Somatic Mutation Detection, Copy Number Variation (CNV) Testing, Single Nucleotide Polymorphism Analysis

2) By Ribonucleic Acid Testing: Gene Expression Profiling, Messenger Ribonucleic Acid Analysis, Non-coding Ribonucleic Acid Detection, Fusion Transcript Detection

3) By Microbial Testing: Urinary Microbiome Profiling, Pathogen Identification, Antimicrobial Resistance Gene Detection, Quantitative Microbial Load Analysis

4) By Epigenetic Testing: Deoxyribonucleic Acid Methylation Analysis, Histone Modification Profiling, Chromatin Accessibility Testing

What are the Emerging Market Trends Driving the Growth of the Genomic Urine Testing Industry?

Top enterprises in the genomic urine testing market are honing their focus on the creation of novel solutions like next-generation sequencing, with the aim to boost precision, sensitivity, and the early identification potential of non-invasive diagnosis tests for a variety of diseases. Next-generation sequencing (NGS) represents a sophisticated technology for DNA sequencing, which makes the fast, correct and large-scale genetic material analysis possible by sequencing millions of DNA fragments at the same time. To illustrate, Convergent Genomics Inc., a biotech firm based in the US, introduced the genomic urine test UroAmp in May 2023. The test utilizes next-generation DNA sequencing to scrutinize mutations in 60 genes linked with bladder cancer, thus facilitating early detection as many as 12 years before clinical symptoms emerge. It offers thorough genetic insights for directing diagnosis, deciding treatment, and monitoring recurrence, hence delivering superior accuracy compared to conventional methods like cytology and cystoscopy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report

Which Regions Are Driving Growth in the Genomic Urine Testing Market?

North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23408

This Report Delivers Insight On:

1. How big is the genomic urine testing market, and how is it changing globally?

2. Who are the major companies in the genomic urine testing market, and how are they performing?

3. What are the key opportunities and risks in the genomic urine testing market right now?

4. Which products or customer segments are growing the most in the genomic urine testing market?

5. What factors are helping or slowing down the growth of the genomic urine testing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model